Akero Therapeutics (AKRO) News Today $46.00 -0.36 (-0.78%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$47.35 +1.35 (+2.94%) As of 05/27/2025 06:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock AKRO Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Akero Therapeutics, Inc. (NASDAQ:AKRO) Shares Acquired by ProShare Advisors LLCProShare Advisors LLC lifted its stake in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 32.4% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 22,398 shares of the company's stock after buying an additional 5,May 27 at 4:12 AM | marketbeat.comD. E. Shaw & Co. Inc. Decreases Stock Position in Akero Therapeutics, Inc. (NASDAQ:AKRO)D. E. Shaw & Co. Inc. lessened its holdings in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 71.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 35,809 shares of the company's stock afterMay 26 at 3:31 AM | marketbeat.comAkero Therapeutics, Inc. (NASDAQ:AKRO) Receives Consensus Rating of "Buy" from BrokeragesShares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) have been assigned an average recommendation of "Buy" from the eight analysts that are currently covering the stock, MarketBeat reports. Eight analysts have rated the stock with a buy rating. The average 1 year price target among bMay 26 at 3:23 AM | marketbeat.comAkero Therapeutics (NASDAQ:AKRO) Stock Price Down 5.9% - Here's What HappenedAkero Therapeutics (NASDAQ:AKRO) Stock Price Down 5.9% - Here's WhyMay 25 at 4:25 PM | marketbeat.comWoodline Partners LP Boosts Stock Position in Akero Therapeutics, Inc. (NASDAQ:AKRO)Woodline Partners LP lifted its stake in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 29.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 379,967 shares of the company's stock after purchasing an additional 87,499 shares duriMay 25 at 4:41 AM | marketbeat.comPatrick Lamy Sells 4,000 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) StockMay 24, 2025 | insidertrades.comRafferty Asset Management LLC Sells 17,797 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO)Rafferty Asset Management LLC reduced its stake in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 19.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 72,604 shares of the company's stock after selling 1May 23, 2025 | marketbeat.comAkero: FGF21 Advancement For MASH Targeting Presses On With Key DevelopmentsMay 21, 2025 | seekingalpha.comWhy Akero Therapeutics, Inc. (AKRO) Skyrocketed TodayMay 21, 2025 | msn.comAkero surges after report on plans for potential saleMay 20, 2025 | msn.com32,150 Shares in Akero Therapeutics, Inc. (NASDAQ:AKRO) Purchased by Tema Etfs LLCTema Etfs LLC acquired a new stake in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 32,150 shares of the company's stock, valued at approximately $894,000. SeveralMay 20, 2025 | marketbeat.comAkero Therapeutics, Inc. (NASDAQ:AKRO) Holdings Reduced by Deutsche Bank AGDeutsche Bank AG lessened its holdings in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 18.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 273,811 shares of the company's stockMay 20, 2025 | marketbeat.comPoint72 Asset Management L.P. Sells 403,643 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO)Point72 Asset Management L.P. reduced its position in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 31.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 899,680 shares of the company's stock afteMay 19, 2025 | marketbeat.comAkero Therapeutics, Inc. (NASDAQ:AKRO) Shares Bought by RTW Investments LPRTW Investments LP raised its position in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 15.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,859,823 shares of the company's sMay 18, 2025 | marketbeat.com30,208 Shares in Akero Therapeutics, Inc. (NASDAQ:AKRO) Bought by Cubist Systematic Strategies LLCCubist Systematic Strategies LLC bought a new position in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The firm bought 30,208 shares of the company's stock, valued at approximately $840,000. A number of other iMay 17, 2025 | marketbeat.comNorthern Trust Corp Increases Stock Position in Akero Therapeutics, Inc. (NASDAQ:AKRO)Northern Trust Corp grew its stake in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 6.1% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 620,321 shares of the company's stock after buying an additional 35,737May 17, 2025 | marketbeat.comAkero Therapeutics, Inc. (NASDAQ:AKRO) Shares Bought by MPM Bioimpact LLCMPM Bioimpact LLC raised its holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 17.3% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 460,617 shares of the company's stock after purchasing an additionaMay 16, 2025 | marketbeat.com66,000 Shares in Akero Therapeutics, Inc. (NASDAQ:AKRO) Purchased by Orbimed Advisors LLCOrbimed Advisors LLC acquired a new stake in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 66,000 shares of the company's stock, valuedMay 15, 2025 | marketbeat.comJanus Henderson Group PLC Sells 1,043,239 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO)Janus Henderson Group PLC trimmed its position in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 14.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,034,239 shares of the company's stock aftMay 15, 2025 | marketbeat.comAkero Therapeutics (NASDAQ:AKRO) Posts Earnings Results, Beats Estimates By $1.90 EPSAkero Therapeutics (NASDAQ:AKRO - Get Free Report) posted its earnings results on Monday. The company reported $0.90 earnings per share for the quarter, beating the consensus estimate of ($1.00) by $1.90.May 14, 2025 | marketbeat.comAkero Therapeutics, Inc. (NASDAQ:AKRO) CEO Sells $1,244,400.00 in StockMay 14, 2025 | insidertrades.comBest Biotech Stocks to Buy in 2025 (AKRO)Discover the best biotech stocks of 2025, including top performers like Vertex and Regeneron, driven by clinical breakthroughs and strong investor momentum.May 13, 2025 | marketbeat.comAkero Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 12, 2025 | globenewswire.comAkero Therapeutics, Inc. (NASDAQ:AKRO) Shares Sold by Algert Global LLCAlgert Global LLC lowered its stake in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 12.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 59,734 shares of the company's stock after sMay 12, 2025 | marketbeat.comThe Manufacturers Life Insurance Company Has $3.47 Million Stake in Akero Therapeutics, Inc. (NASDAQ:AKRO)The Manufacturers Life Insurance Company grew its stake in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 29.0% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 124,592 shares of the company's stock after buying an additional 28,043 sharMay 12, 2025 | marketbeat.comDimensional Fund Advisors LP Boosts Stake in Akero Therapeutics, Inc. (NASDAQ:AKRO)Dimensional Fund Advisors LP grew its stake in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 6,229.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 449,110 shares of the company's stock after acquiring an addMay 12, 2025 | marketbeat.comAkero Therapeutics Presents Week 96 Results from Phase 2b SYMMETRY Clinical Trial of Efruxifermin in Patients with Compensated Cirrhosis Caused by MASH Showing Fibrosis ...May 11, 2025 | seekingalpha.comFred Alger Management LLC Decreases Holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO)Fred Alger Management LLC lowered its holdings in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 2.3% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 263,353 shares of the company's stock after selling 6,248 shares during thMay 11, 2025 | marketbeat.comAkero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025May 10, 2025 | globenewswire.comPatrick Lamy Sells 8,000 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) StockMay 10, 2025 | insidertrades.comBalyasny Asset Management L.P. Invests $18.06 Million in Akero Therapeutics, Inc. (NASDAQ:AKRO)Balyasny Asset Management L.P. bought a new position in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 649,134 shares of the company's stock, valued at aMay 10, 2025 | marketbeat.comAkero Therapeutics Inc.: Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Trial in the New England Journal of MedicineMay 9, 2025 | finanznachrichten.deDeep Track Capital LP Purchases 800,216 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO)Deep Track Capital LP boosted its position in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 116.0% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,490,000 shares of the company's stock after purchasing an adMay 9, 2025 | marketbeat.comAkero Therapeutics Presents Week 96 Results from Phase 2b SYMMETRY Clinical Trial of Efruxifermin in Patients with Compensated Cirrhosis Caused by MASH Showing Fibrosis Improvement without Worsening of MASH at the EASL Congress 2025May 9, 2025 | globenewswire.comTimothy Rolph Sells 12,500 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) StockMay 9, 2025 | insidertrades.comAkero Therapeutics Announces Publication of Phase 2b SYMMETRY Trial in the New England Journal of MedicineMay 9, 2025 | globenewswire.comAkero Therapeutics Presents Week 96 Results from Phase 2b SYMMETRY Clinical Trial of Efruxifermin in Patients with Compensated Cirrhosis Caused by MASH Showing Fibrosis Improvement without Worsening of MASH at the EASL Congress 2025May 9, 2025 | globenewswire.comCutter Capital Management LP Invests $6.40 Million in Akero Therapeutics, Inc. (NASDAQ:AKRO)Cutter Capital Management LP acquired a new stake in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 230,000 shares of theMay 8, 2025 | marketbeat.comAkero Therapeutics to Present at the BofA Securities 2025 Healthcare ConferenceMay 7, 2025 | globenewswire.comSusquehanna Fundamental Investments LLC Buys New Stake in Akero Therapeutics, Inc. (NASDAQ:AKRO)Susquehanna Fundamental Investments LLC bought a new stake in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 8,390 shares of the company's stock, valued at approximately $233May 7, 2025 | marketbeat.comRenaissance Technologies LLC Invests $579,000 in Akero Therapeutics, Inc. (NASDAQ:AKRO)Renaissance Technologies LLC acquired a new position in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 20,800 shares of the company's stock, valuedMay 6, 2025 | marketbeat.comAlkeon Capital Management LLC Sells 1,563,736 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO)Alkeon Capital Management LLC reduced its position in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 47.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,761,268 shares of tMay 5, 2025 | marketbeat.com165,000 Shares in Akero Therapeutics, Inc. (NASDAQ:AKRO) Acquired by 5AM Venture Management LLC5AM Venture Management LLC bought a new stake in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 165,000 shares of the company's stock, valued at approximately $4,5May 4, 2025 | marketbeat.comAkero Therapeutics, Inc. (NASDAQ:AKRO) Shares Sold by Schonfeld Strategic Advisors LLCSchonfeld Strategic Advisors LLC lessened its holdings in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 5.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 262,295 shares of the coMay 4, 2025 | marketbeat.comAquatic Capital Management LLC Buys 14,841 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO)Aquatic Capital Management LLC lifted its position in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 463.8% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 18,041 shares of the company's stock after purchasing an additional 14,841 shaMay 4, 2025 | marketbeat.comAkero Therapeutics (AKRO) Projected to Post Quarterly Earnings on FridayAkero Therapeutics (NASDAQ:AKRO) will be releasing its Q1 2025 earnings before the market opens on Friday, May 9. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-9-akero-therapeutics-inc-stock/)May 4, 2025 | marketbeat.comAkero Therapeutics, Inc. (NASDAQ:AKRO) Receives Consensus Rating of "Buy" from AnalystsAkero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) has been assigned an average rating of "Buy" from the nine brokerages that are covering the stock, Marketbeat Ratings reports. Nine research analysts have rated the stock with a buy recommendation. The average 1-year price objective among brMay 2, 2025 | marketbeat.comAkero Therapeutics, Inc. (NASDAQ:AKRO) Shares Purchased by Tower Research Capital LLC TRCTower Research Capital LLC TRC lifted its position in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 770.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 16,188 shMay 2, 2025 | marketbeat.comEmerald Mutual Fund Advisers Trust Has $9.80 Million Stock Position in Akero Therapeutics, Inc. (NASDAQ:AKRO)Emerald Mutual Fund Advisers Trust reduced its stake in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 15.2% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 352,180 shares of the company's stock after selling 63,021 shares during the pMay 1, 2025 | marketbeat.comAkero Therapeutics, Inc. (NASDAQ:AKRO) Insider Timothy Rolph Sells 6,250 SharesAkero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) insider Timothy Rolph sold 6,250 shares of the stock in a transaction dated Thursday, April 24th. The shares were sold at an average price of $41.03, for a total value of $256,437.50. Following the completion of the transaction, the insider now directly owns 169,721 shares in the company, valued at $6,963,652.63. This represents a 3.55 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.April 30, 2025 | marketbeat.com Get Akero Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AKRO and its competitors with MarketBeat's FREE daily newsletter. Email Address AKRO Media Mentions By Week AKRO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AKRO News Sentiment▼0.751.03▲Average Medical News Sentiment AKRO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AKRO Articles This Week▼118▲AKRO Articles Average Week Get Akero Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AKRO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Intra-Cellular Therapies News Genmab A/S News Dr. Reddy's Laboratories News Moderna News Ascendis Pharma A/S News Viatris News Qiagen News Roivant Sciences News Revolution Medicines News Blueprint Medicines News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AKRO) was last updated on 5/28/2025 by MarketBeat.com Staff From Our PartnersTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akero Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
